全球指数

HENLIUS BIOTECH(2696.HK):STRONG SALES POWERED BY EXPANDING PRODUCTION CAPACITY

招银国际证券有限公司2022-03-18
Strong revenue growth and improving operating margins. Henlius’s 2021 revenue increased 186% YoY to RMB1.68bn, mainly driven by the strong sales growth of HANQUYOU (trastuzumab biosimilar) and HANLIKANG (rituximab biosimilar), recording RMB930mn (+584% YoY) and RMB543mn (+88% YoY) in revenue, respectively. Selling expense ratio decreased from 41.5% in 2020 to 30.9% in 2021, and administration expense ratio decreased from 32.8% in 2020 to 16.7% in 2021, showing the Company’s improving operating efficiency and strong economy of scale. R&D expense was RMB1.76bn, and net loss was RMB984mn in 2021. As of the end of 2021, Henlius had RMB707.3mn cash on hand.
Remarkable commercial progress of the four marketed biosimilar products. HANQUYOU (trastuzumab), marketed by the Company’s in-house team in China, recorded RMB930mn revenue in 2021, including RMB62mn sales from overseas. For the global market, HANQUYOU is the only Chinese biosimilar approved in the EU and has been marketed in nearly 20 European counties. Henlius also partners with Intas in North America, with the US FDA filing of HANQUYOU expected this year. In addition to NHL and CLL, HANLIKANG (rituximab) was approved for the treatment of rheumatoid arthritis (RA) in China, for which the originator rituximab has not been approved in China, and recorded RMB543mn revenue in 2021. HANDAYUAN (adamumab) realized RMB22mn sales in 2021. HANBEITAI (bevacizumab) was approved in Nov 2021 for mCRC and NSCLC.
Serplulimab (PD-1) to be commercialized in the near future. We expect serplulimab to be approved in China for MSI-H solid tumors in 2Q22.
Serplulimab has passed the GMP on-site inspection, and its commercial team is ready (team size to reach 200 in 1Q22). The NDA of serplulimab for 1L sq- NSCLC was accepted by NMPA in Sep 2021 and is expected to be approved in 2H22. Additionally, the phase 3 Ztrial for ES-SCLC has met the primary endpoint in Dec 2021 with encouraging OS data, with NDAs in China and EU expected in 2022.
To break the bottleneck in manufacturing. Xuhui Facility (24,000L) has received dual GMP certification from China and EU, and completed 350+ batches productions with over 98% success rate. Songjiang First Plant (24,000L) has completed construction and equipment verification, and has received the manufacturing certificate for HANQUYOU. We expect the Plant to be officially in use by mid-2022, which will bring the total capacity to 48,000L.
Additionally, Songjiang Second Plant stage 1&2 (36,000L) is expected to complete the first batch production by the end of 2022, with potential to add additional 60,000L (stage 3) in the future.
Maintain BUY. We revised our DCF-based TP to HK$29.85 based on a DCF valuation (WACC: 12.23%, terminal growth rate: 2%).

免责声明

以上内容仅供您参考和学习使用,任何投资建议均不作为您的投资依据;您需自主做出决策,自行承担风险和损失。九方智投提醒您,市场有风险,投资需谨慎。

推荐阅读

暂无数据

公司动态

    暂无数据

盘面综述

    暂无数据

IPO动态

    暂无数据

港股涨幅榜
  • 港股通
  • 红筹股
  • 国企股
  • 科技股
  • 名称/代码
  • 最新价
  • 涨跌幅

暂无数据

扫码关注

九方智投公众号

扫码关注

九方智投公众号